- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Meta-Analysis Finds L-Carnitine Supplementation Reduces CV Risk Factors in Diabetic and Glucose Intolerant Patients
![Meta-Analysis Finds L-Carnitine Supplementation Reduces CV Risk Factors in Diabetic and Glucose Intolerant Patients Meta-Analysis Finds L-Carnitine Supplementation Reduces CV Risk Factors in Diabetic and Glucose Intolerant Patients](https://medicaldialogues.in/h-upload/2024/08/09/750x450_247074-l-carnitine-supplementation.webp)
Iran: A recent systematic review and dose-response meta-analysis has examined the impact of L-carnitine supplementation on cardiovascular risk factors in individuals with impaired glucose tolerance and diabetes.
This meta-analysis revealed that L-carnitine supplementation significantly reduces levels of triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), HbA1c, HOMA-IR, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), as well as weight, body mass index (BMI), body fat percentage (BFP), and leptin in patients with diabetes and impaired glucose tolerance. However, no significant effects were observed on total cholesterol (TC), high-density lipoprotein (HDL), serum insulin, systolic blood pressure (SBP), diastolic blood pressure (DBP), apolipoprotein A (apo A), or apolipoprotein B (apo B) in these patients.
The findings were published online in Diabetology & Metabolic Syndrome on July 31, 2024.
L-carnitine is often touted for its potential benefits in enhancing exercise performance and weight management. However, its effects on cardiovascular health, particularly in diabetic and pre-diabetic populations, have been less clear. Therefore, Rezvan Gheysari, Shohada-E-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, and colleagues aimed to assess the effect of L-carnitine supplementation on CVD risk factors.
For this purpose, the researchers conducted a systematic literature search in PubMed, Web of Science, and Scopus until October 2022. The primary outcomes assessed included lipid profiles, insulin resistance, anthropometric measurements, leptin, serum glucose levels, blood pressure, and inflammatory markers. A random-effects model was used to calculate the pooled weighted mean difference (WMD).
The researchers reported the following findings:
- The study included 21 RCTs (n = 2900) with 21 effect sizes.
- L-carnitine supplementation had a significant effect on TG (WMD = − 13.50 mg/dl), LDL (WMD = − 12.66 mg/dl), HbA1c (WMD = -0.37%), FBG (WMD = − 6.24 mg/dl), HOMA-IR (WMD = -0.72), CRP (WMD = − 0.07 mg/dl), TNF-α (WMD = − 1.39 pg/ml), weight (WMD = − 1.58 kg), BFP (WMD = − 1.83), BMI (WMD = − 0.28 kg/m2), and leptin (WMD = − 2.21 ng/ml) in intervention, compared to the placebo group, in the pooled analysis.
The analysis also indicated that the optimal duration for L-carnitine supplementation to effectively reduce FBG, HbA1c, and HOMA-IR was approximately 50 weeks after initiation. It was noted that longer durations of supplementation (≥ 25 weeks) had a diminishing impact on weight.
"Given the significant risk of bias present in the majority of the included trials, further well-designed and comprehensive RCTs with larger sample sizes and robust analytical methods are needed to more accurately determine the influence of L-carnitine on cardiovascular disease (CVD) risk factors in individuals with diabetes and glucose intolerance," the researchers concluded.
Reference:
Gheysari, R., Nikbaf-Shandiz, M., Hosseini, A.M. et al. The effects of L-carnitine supplementation on cardiovascular risk factors in participants with impaired glucose tolerance and diabetes: a systematic review and dose–response meta-analysis. Diabetol Metab Syndr 16, 185 (2024). https://doi.org/10.1186/s13098-024-01415-8
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751